Tomahawk, WI 06/12/2014 (Basicsmedia) – Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has powered up from 2.88 to 7.29, almost 169% in this week’s trade activity. Investors smell an anticipated sellout of ACHN to some bigger health care or pharmaceutical firm, as a key industry players are targeting the exquisite Hepatitis C drug manufacturers and researchers across the US, since these drugs provide a robust profit-push!

IDIX’s Acquisition A Clarion Call For Investors

Merck & Co., Inc. (NYSE:MRK), a healthcare company of repute bagged the dominance and controllability of Idenix Pharmaceuticals Inc (NASDAQ:IDIX) on Monday, June 9, 2014. The IDIX sellout was a big news, as there were quite a few other bidders, besides MRK; however, the latter bagged the deal at $3.85 billion. IDIX’s shares witnessed an unprecedented step up – surging up from a meek 7.175 till the end of last week, escalating to a whopping 24.00 at the scratch of this week, steadying itself near that mark, consequently.

MRK’s strategic acquisition was solicited at a juncture when IDIX brags about quite a few top notch Heaptitis-C drug compositions under its disposition, in the pipeline. There are two undergoing Phase2 trials, one undergoing Phase1 trials, whereas another is facing the preclinical trials. Moreover, IDIX claimed that Gilead Sciences, Inc. (NASDAQ:GILD) of Sovaldi fame, has infringed upon its earlier patents. Investors have retrenched from investing upon GILD, after IDIX hurled accusations on patent issues.

ACHN Sellout Imminent!

The IDIX-MRK has left investors pumped up, and they feel ACHN shall follow suit. This resulted in a sharp rise in ACHN’s price over the past four days. All and sundry witnessed that MRK had to face tough competition from a pharma giant – AbbVie Inc (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ), a renowned name in the healthcare industry.

ACHN has an exquisite portfolio pipeline comprising NS5A-Inhibitor ACH-3102, a phenomenal NS3/4-Inhibitor ACH-2684 and the most useful NS5B-Inhibitor ACH-3422. Anticipations are rife among the investor fraternity that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shall have a list of noteworthy acquirers, who intends to add this Hepatitis C drug manufacturer, to their shopping baskets!

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.